Journal of Advanced Zoology
ISSN: 0253-7214
Volume 44 Issue S-06 Year 2023 Page 2265:2272

Genetic Basis And Clinical Perspectives Of Breast Cancer

Bidisha Ghosh[1], Monoswita Chakraborty[2], Semanti Ghosh[3], Bidisha Ghosh[4], Subhasis Sarkar[5], Suranjana Sarkar[6*]

[1]*Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal700121, Email: bidishaghosh076@gmail.com, Ph: 9330493223*
[2]*Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal700121, Email: monoswitachakraborty@gmail.com, Ph: 7478279904*
[3]*Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121, Email: semantig@svu.ac.in, Ph- 9432912893*
[4]*Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121, Email: bidishag@svu.ac.in, Ph- 8017314552*
[5]*Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121, Email: subhasiss@svu.ac.in, Ph- 960919374*
[6*]*Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121, Email: suranjanas@svu.ac.in, Ph: 8981278415*

***Corresponding Author**:Suranjana Sarkar*
**Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121, Email: suranjanas@svu.ac.in, Ph: 8981278415*

Article History

***Received:** 30/09/2023*
***Revised:** 05/10/2023*
***Accepted:**03/11/2023*

Abstract

Breast cancer, a widespread malignancy affecting women, originates in the epithelial tissues of the breast. This study explores the significance of BRCA1 and BRCA2 genes in breast cancer etiology. Approximately 5% to 10% of breast cancer cases are hereditary, resulting from germline mutations in these genes. BRCA mutations increase the risk of breast cancer, with carriers facing a likelihood of 45% to 75% of developing the disease. Additionally, the aggressive phenotype of BRCA-related breast cancers is marked by features like triple-negative attributes and higher grades.

In India, the incidence of breast cancer is escalating, projected to reach 250,000 cases by 2030. Alarming mortality rates underscore the necessity for effective interventions. The five-stage classification of breast cancer—from non-invasive disease in Stage 0 to metastatic spread in Stage IV—provides a framework for diagnosis and treatment. Early-stage breast cancers are manageable with surgery and hormone therapy. In locally advanced breast cancer (Stage III), a combination of chemotherapy and surgery is employed after metastatic spread to lymph nodes and other sites. Stage IV breast cancer, representing the most advanced phase, presents significant treatment challenges. Current therapies encompass systemic drugs, radiation therapy, chemotherapy, and surgery, although achieving a definitive cure remains elusive.

	This study emphasizes the crucial role of BRCA mutations in breast cancer susceptibility, stressing the importance of genetic screening and targeted interventions. Furthermore, it explores the complexities of disease staging, guiding treatment strategies based on disease extent. Despite considerable progress, continuous research efforts are essential to enhancing diagnostic precision and developing more effective treatments for this intricate and multifaceted disease (Łukasiewicz et al., 2021; Smolarz et al., 2022).
	***Keywords:* Breast cancer, BRCA mutations, Disease staging, Hereditary risk, Treatment strategies**

Introduction

Breast cancer, a complex and widespread malignancy, stands as one of the most prevalent and formidable diseases globally, particularly impacting women. Rooted in the uncontrolled proliferation of abnormal cells within the epithelial tissues of the breast, this multifaceted disease presents a diverse array of subtypes and stages that warrant meticulous scientific investigation.

At the molecular level, the pathogenesis of breast cancer involves genetic and molecular alterations that drive aberrant cell growth. Advances in genomics and molecular biology have shed light on critical factors in breast cancer etiology, with the BRCA1 and BRCA2 genes occupying a central role. Germline mutations in these genes contribute significantly to hereditary breast cancer, constituting approximately 5% to 10% of cases. Carriers of BRCA mutations face an elevated risk, ranging from 45% to 75%, of developing breast cancer, often characterized by aggressive phenotypes marked by triple-negative attributes and higher grades (Łukasiewicz *et al*., 2021 ; Smolarz *et al*., 2022).

Beyond its molecular intricacies, breast cancer has profound implications for public health, extending into psychosocial dimensions. The urgency to address breast cancer is underscored by its widespread prevalence, impacting millions globally and necessitating comprehensive strategies for prevention, early detection, and treatment.

Types of Breast Cancer

Breast cancer is a diverse disease with distinct subtypes characterized by variations in biological features, clinical behavior, and treatment responses. The categorization of breast cancer is determined by the presence or absence of specific molecular markers and receptors. The primary classifications of breast cancer encompass (Nounou *et al*., 2015; Feng *et al*.,2018):

1. Ductal Carcinoma In Situ (DCIS): DCIS is recognized as a non-invasive or pre-invasive form of breast cancer, involving abnormal cells within the breast duct lining without infiltration into adjacent tissues. Typically identified through mammography.

2. Invasive Ductal Carcinoma (IDC): IDC stands as the predominant form of invasive breast cancer, constituting approximately 80% of cases. Originating in the milk ducts, it progresses to invade neighboring breast tissues and may manifest as a palpable lump or thickening.

3. Invasive Lobular Carcinoma (ILC): ILC initiates in the milk-producing glands (lobules) and displays a distinctive growth pattern, often characterized by a single-file line of cells. ILC accounts for around 10-15% of invasive breast cancers.

4. Triple-Negative Breast Cancer (TNBC): TNBC lacks expression of estrogen receptors (ER) and progesterone receptors (PR) and does not exhibit HER2/neu overexpression. This subtype tends to be more aggressive, with limited targeted treatment options, often necessitating a combination of chemotherapy and surgery.

5. HER2-Positive Breast Cancer: HER2-positive breast cancer involves an overexpression of the human epidermal growth factor receptor 2 (HER2/neu). While generally more aggressive, targeted therapies like trastuzumab (Herceptin) have significantly improved outcomes.

6. Luminal A and Luminal B Subtypes: Luminal A and Luminal B subtypes are characterized by the presence of hormone receptors (ER and/or PR). Luminal A tumors, less aggressive, respond well to hormone therapy, while Luminal B tumors with higher proliferation rates may require additional treatment.

7. Inflammatory Breast Cancer (IBC): IBC, a rare and aggressive form, manifests with redness, swelling, and warmth in the breast. Often lacking a distinct lump, it is frequently diagnosed at a more advanced stage.

8. Metaplastic Breast Cancer: Metaplastic breast cancer, a rare subtype, presents with both cancerous and non-cancerous cells. It typically carries a poorer prognosis and may exhibit resistance to standard treatments.

9. HER2-Enriched Subtype: HER2-enriched breast cancer, identified through gene expression profiling, showcases elevated HER2/neu expression, potentially benefiting from targeted therapies.

Genes Involved

Breast cancer is intricately linked to genetic factors, and among the key genes associated with its initiation and progression, BRCA1 (Breast Cancer Gene 1) and BRCA2 (Breast Cancer Gene 2) play pivotal roles. These genes are essential for maintaining genomic stability, regulating cell cycles, and preventing tumor formation (Shiovitz, 2015; Criscitiello *et al*., 2022).

1. BRCA1:

Function: BRCA1 is integral to DNA repair, cell cycle regulation, and maintaining genomic integrity, acting as a tumor suppressor gene.

Mutation Impact: Disruption of BRCA1's normal functions due to mutations significantly elevates the risk of breast and ovarian cancers.

Hereditary Risk: Inheriting a mutated BRCA1 gene substantially increases the risk of developing breast and ovarian cancers, with estimates ranging from 55-65% for breast cancer.

The BRCA1 (Breast Cancer Gene 1) gene assumes a pivotal role in the context of breast cancer, acting as a crucial regulator of cellular processes that preserve the integrity of normal breast tissue. Functioning as a tumor suppressor gene, BRCA1 is primarily responsible for repairing damaged DNA, especially in response to double-strand breaks stemming from various factors. Its regulatory influence extends to the cell cycle, ensuring systematic progression and averting uncontrolled cell division. By serving as a guardian of genomic stability, BRCA1 plays a crucial role in suppressing the formation and growth of tumors. Mutations in the BRCA1 gene, particularly those inherited, can compromise its tumor-suppressing function, heightening the risk of breast cancer. Women with a mutated BRCA1 gene typically face an increased likelihood of developing breast cancer, often at an earlier age compared to those without the mutation. Additionally, BRCA1 is involved in repairing DNA cross-links and plays a key role in homologous recombination, essential mechanisms for preserving the integrity of genetic material. Recognizing the role of BRCA1 in breast cancer is imperative for genetic counseling, risk assessment, and the implementation of preventive measures, including proactive surveillance and risk-reducing strategies (Lee *et al*., 2020; Fu *et al*., 2022).

2. BRCA2:

Function: Similar to BRCA1, BRCA2 is crucial for DNA repair and maintaining genomic stability.

Mutation Impact: Mutations in BRCA2 compromise DNA repair processes, leading to an increased susceptibility to cancer development.

Hereditary Risk: Individuals with BRCA2 mutations face an elevated risk of breast cancer, estimated at 45-55%, along with an increased risk of other cancers such as ovarian, pancreatic, and prostate cancers.

The BRCA2 (Breast Cancer Gene 2) gene assumes a critical role in maintaining genomic stability and preventing the onset of breast cancer. Analogous to BRCA1, BRCA2 functions as a tumor suppressor gene, primarily involved in intricate DNA repair processes, particularly in response to double-strand breaks. Its crucial participation in homologous recombination, a fundamental mechanism for accurately mending DNA double-strand breaks, underscores its significance in preserving genomic integrity. Beyond its role in DNA repair, BRCA2 acts as a guardian against uncontrolled cell growth and the formation of tumors. Mutations in BRCA2 compromise its tumor-suppressing function, significantly increasing the risk of breast cancer. Inherited mutations in BRCA2 (Paul and Paul, 2014) elevate the likelihood of developing breast cancer, often manifesting at an earlier age compared to those without the mutation. Additionally, BRCA2 mutations are associated with an increased risk of other cancers, including ovarian, pancreatic, and prostate cancers. A comprehensive understanding of BRCA2's functions is vital for genetic counseling, risk assessment, and implementing preventive measures. Genetic testing for BRCA2 mutations, especially in individuals with a familial history of breast or ovarian cancer, facilitates proactive management strategies such as heightened surveillance, risk-reducing surgeries, or targeted therapies. Recognition of the multifaceted role of BRCA2 contributes to a nuanced approach in addressing hereditary aspects of breast cancer, enabling tailored interventions for individuals at elevated risk (Lee *et al*., 2020; Fu *et al*., 2022).

3. TP53 (Tumor Protein p53):

Function: TP53, a tumor suppressor gene, regulates cell division and inhibits tumor formation.

Mutation Impact: Mutations in TP53 are linked to an increased risk of various cancers, including aggressive forms of breast cancer.

The TP53 gene, responsible for encoding the tumor protein p53, plays a crucial role in safeguarding genomic integrity and preventing the onset of cancer, including breast cancer. Operating as a tumor suppressor gene, TP53 orchestrates cellular responses to various stresses, regulating the cell cycle, and impeding the formation of tumors. The p53 protein, generated by TP53, diligently monitors the cell cycle, pausing progression in the face of DNA damage to facilitate repair or triggering programmed cell death (apoptosis) if the damage proves irreparable. Beyond its cell cycle regulatory function, TP53 is instrumental in DNA repair mechanisms, contributing significantly to the maintenance of genomic stability. When confronted with severe DNA damage, p53's activation of apoptotic pathways eliminates cells harboring irreparable genetic alterations, preventing the propagation of potentially cancerous cells. Furthermore, p53 suppresses angiogenesis, inhibiting the formation of new blood vessels crucial for tumor growth. In the context of breast cancer, mutations in TP53 are associated with a heightened risk, often correlating with more aggressive tumor phenotypes. Alterations in TP53 can compromise its tumor-suppressing functions, allowing cells with damaged DNA to evade apoptosis and persist, contributing to breast cancer development and progression. Recognizing the role of TP53 in breast cancer is paramount for evaluating risk, prognosis, and devising potential treatment strategies, given its implications in driving cancer progression and influencing therapeutic responses. While TP53 mutations are not as prevalent as BRCA1 or BRCA2 mutations in hereditary breast cancer, their significance in the broader landscape of breast cancer biology underscores the importance of understanding their mechanisms and impact (Shahbandi *et al*., 2020).

4. CHEK2 (Checkpoint Kinase 2):

Function: CHEK2 is involved in cell cycle regulation and DNA repair mechanisms.

Mutation Impact: Mutations in CHEK2 are associated with an elevated risk of breast cancer, particularly in specific populations.
Checkpoint Kinase 2 (CHEK2) is a pivotal factor in preserving genomic stability and preventing cancer, with a particular relevance to breast cancer. Operating as a crucial component within the DNA damage response pathway, CHEK2 acts as a vigilant monitor of genome integrity. It detects instances of DNA damage and orchestrates precise cellular responses. Its primary function lies in regulating the cell cycle, activating checkpoints in response to DNA damage to temporarily halt cell division, providing a window for effective DNA repair. As a tumor suppressor gene, mutations in CHEK2 can compromise its ability to regulate the cell cycle and respond effectively to DNA damage. Certain mutations in CHEK2 have been identified as contributors to an increased risk of breast cancer, particularly prevalent in specific populations, albeit with a lower penetrance compared to genes like BRCA1 or BRCA2. Inherited mutations in CHEK2 play a role in hereditary breast cancer, influencing an individual's susceptibility to breast cancer, often in combination with additional genetic or environmental factors. The identification of CHEK2 mutations, especially in individuals

with a familial history of breast cancer, holds clinical significance, guiding decisions related to screening, surveillance, and risk-reducing interventions. This information proves invaluable for tailoring personalized management strategies based on an individual's genetic profile (Apostolou *et al*., 2017).

Cell Signaling Pathways Involved

Breast cancer is characterized by intricate and dysregulated cell signaling processes that contribute to the initiation, progression, and metastasis of tumors. Several key signaling pathways play crucial roles in breast cancer development (Ortega *et al*., 2020):

1. Estrogen Receptor Signaling: Hormone receptor status, particularly estrogen receptor (ER) signaling, is pivotal in breast cancer. ER-positive breast cancers depend on estrogen for growth, and therapies targeting this pathway, such as tamoxifen, aim to block estrogen's effects.

2. HER2/neu Signaling: The Human Epidermal Growth Factor Receptor 2 (HER2/neu) pathway is often overactivated in breast cancer, leading to increased cell proliferation. HER2-positive breast cancers can be targeted with HER2-directed therapies like trastuzumab.

3. PI3K/AKT/mTOR Pathway: The PI3K/AKT/mTOR pathway is frequently dysregulated in breast cancer, promoting cell survival and proliferation. Inhibitors targeting this pathway, such as everolimus, are employed in specific cases to impede tumor growth.

4. MAPK/ERK Signaling: The Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase (MAPK/ERK) pathway is involved in cell cycle regulation and is often hyperactivated in breast cancer. Targeting this pathway is an active area of research for potential therapeutic interventions.

5. Wnt/β-Catenin Pathway: The Wnt/β-Catenin pathway regulates cell fate and differentiation. Aberrations in this pathway are associated with breast cancer, and targeting components like β-catenin presents a potential avenue for therapeutic intervention.

6. Notch Signaling: Notch signaling is crucial for cell differentiation, and dysregulation is implicated in breast cancer. Inhibitors targeting the Notch pathway are being explored for their potential in breast cancer treatment.

7. TGF-β Signaling: Transforming Growth Factor-β (TGF-β) signaling has dual roles in breast cancer, acting as a tumor suppressor in early stages and promoting invasion and metastasis in later stages. Therapies modulating TGF-β activity are being investigated.

8. Hedgehog Pathway: The Hedgehog pathway regulates cell differentiation, and its dysregulation is associated with breast cancer. Inhibitors targeting this pathway are under investigation for their potential therapeutic benefits.

Detection

Breast cancer detection involves a range of methods aimed at identifying potential abnormalities or indicators of cancerous cells within the breast tissue. Individuals can actively participate in breast self-examination (BSE), conducting regular checks for changes, lumps, or abnormalities. Clinical breast examination (CBE) by healthcare professionals during routine check-ups contributes to identifying palpable abnormalities. Mammography, utilizing low-dose X-rays, remains a standard screening method, particularly for women over 40 or those at higher risk. Complementary to mammography, breast ultrasound employs sound waves to provide detailed images, especially useful for women with dense breast tissue. Breast magnetic resonance imaging (MRI), utilizing magnetic fields and radio waves, is recommended for high-risk individuals or those with specific abnormalities. Biopsy, involving the removal of suspicious tissue for analysis, serves as a definitive diagnostic tool. Genetic testing, particularly for BRCA1 and BRCA2 mutations, aids in assessing the risk of developing breast cancer, while liquid biopsy, analyzing blood or bodily fluids, holds promise for non-invasive cancer detection. These diverse detection strategies, often personalized based on risk factors and medical history, underscore the importance of regular screenings, early detection, and collaborative efforts with healthcare professionals in improving breast cancer outcomes. Advances in technology and ongoing research continually enhance the array of tools available for effective breast cancer detection (Bhushan *et al*., 2021).

Treatment

Breast cancer treatment is a holistic and personalized strategy aimed at eliminating or controlling the growth of cancer cells, alleviating symptoms, and enhancing the overall quality of life for individuals diagnosed with this disease. Treatment plans are meticulously crafted, considering factors such as the type and stage of breast cancer, hormone receptor status, genetic elements, and the patient's general health. Central to these interventions is surgery, encompassing lumpectomy or mastectomy, often followed by reconstructive procedures post-mastectomy. Radiation therapy employs high-energy beams to target and eliminate cancer cells, frequently used post-surgery to mitigate the risk of recurrence. Chemotherapy utilizes drugs to impede cancer cell growth, administered either before or after surgery, particularly in cases of metastasis. Hormone therapy is employed for hormone receptor-positive cancers, blocking estrogen and progesterone. Targeted therapies focus on specific molecules involved in cancer growth, such as HER2-targeted drugs for HER2-positive breast cancers. While immunotherapy is in experimental stages, it holds promise as an emerging treatment avenue. Additional strategies include adjuvant and neoadjuvant therapy, bone-directed therapy for metastasis, and ongoing clinical trials exploring innovative approaches. Multidisciplinary collaboration ensures a personalized and comprehensive approach to breast cancer treatment, while ongoing research contributes to refining options, fostering optimism for improved outcomes and an enhanced quality of life (Moo *et al*., 2018).

Challenges

Overcoming challenges in the battle against breast cancer involves addressing barriers across prevention, early detection, treatment, and support. Limited healthcare access, particularly in rural or underserved areas, impedes timely diagnosis and treatment. Late-stage diagnoses persist due to a lack of awareness and cultural stigmas, diminishing treatment options. Socioeconomic and racial disparities in screening and diagnosis underscore the need for equitable healthcare access. Barriers to genetic counseling and testing, along with the management of treatment side effects, pose ongoing challenges. Resistance to standard treatments necessitates research into alternative therapies, while limited access to targeted treatments remains an issue in certain regions. Providing psychosocial support and survivorship programs is crucial, alongside efforts to secure research funding, promote collaboration, and enhance patient education. Long-term survivorship care and addressing the mental health impact of breast cancer are increasingly important as survivorship rates improve. A comprehensive, collaborative approach is essential to address these challenges and make significant progress in breast cancer care and outcomes.

Future Prospect

The future outlook in the battle against breast cancer holds tremendous promise, driven by continuous advancements in research, technology, and healthcare strategies. Precision medicine, leveraging genomic profiling, is poised to revolutionize treatment approaches by tailoring interventions based on the unique genetic composition of individual tumors, optimizing therapeutic outcomes while minimizing adverse effects. Ongoing innovations in early detection, including liquid biopsies and advanced imaging technologies, present opportunities for more precise and less invasive diagnostic methods, ultimately contributing to enhanced patient outcomes. The relentless development of targeted therapies and immunotherapies, particularly for aggressive subtypes like triple-negative breast cancer, continues to expand treatment options. Moreover, the integration of artificial intelligence and machine learning stands to elevate diagnostic accuracy, predict treatment responses, and facilitate the implementation of personalized medicine. Collaborative initiatives among researchers, healthcare providers, advocacy groups, and policymakers will be pivotal in ensuring the global dissemination and equitable access to these groundbreaking innovations. Increased awareness, education, and advocacy efforts will empower individuals for proactive breast health management and foster a supportive environment for those affected. The forthcoming era is poised to witness a comprehensive and integrated approach, ushering in advancements in prevention, early detection, and personalized, effective treatments in the collective pursuit against breast cancer.

Conclusion

In conclusion, the intricate landscape of breast cancer necessitates a comprehensive and collaborative approach, integrating advancements in research, technology, and healthcare strategies. The challenges, spanning limited healthcare access to disparities in screening and treatment, underscore the imperative for global initiatives to ensure equitable access and improved outcomes. The future prospects, however, are promising, with precision medicine, innovations in early detection, and targeted therapies leading the way for more effective, personalized interventions. The integration of artificial intelligence and machine learning into diagnostics heralds a synergistic era between technology and medicine, promising enhanced patient care. Ongoing efforts by researchers, healthcare providers, advocacy groups, and policymakers will be pivotal in translating these advancements into tangible benefits for individuals worldwide. Moreover, heightened awareness, education, and advocacy will empower individuals to proactively manage their breast health. The future of breast cancer management envisions a transformative shift—a shift towards a more precise, compassionate, and globally accessible approach that aims not only for effective treatment but also for prevention and early detection. Through collective dedication and sustained innovation, we aspire to shape a future where the impact of breast cancer is minimized, allowing individuals facing this diagnosis to navigate their journey with hope and resilience.

Acknowledgements

The authors express their sincere gratitude to the higher authorities of Swami Vivekananda University and the School of Life Sciences for their unwavering support and for fostering an environment of excellence.

Author Contribution

Data collection and analysis for this project were skillfully carried out by a team comprising Bidisha Ghosh and Monoswita Chakraborty,. The conceptualization, design, and comprehensive refinement of the article were led by Suranjana Sarkar, Dr. Semanti Ghosh, Bidisha Ghosh, and Dr. Subhasis Sarkar.

Conflict of Interest

The authors declare that there are no conflicts of interest.

References:

1. Apostolou, P., & Papasotiriou, I. (2017). Current perspectives on CHEK2 mutations in breast cancer. *Breast cancer (Dove Medical Press)*, *9*, 331–335. https://doi.org/10.2147/BCTT.S111394
2. Bhushan, A., Gonsalves, A., & Menon, J. U. (2021). Current State of Breast Cancer Diagnosis, Treatment, and Theranostics. *Pharmaceutics*, *13*(5), 723. https://doi.org/10.3390/pharmaceutics13050723
3. Criscitiello, C., & Corti, C. (2022). Breast Cancer Genetics: Diagnostics and Treatment. *Genes*, *13*(9), 1593. https://doi.org/10.3390/genes13091593
4. Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., Liu, B., Lei, Y., Du, S., Vuppalapati, A., Luu, H. H., Haydon, R. C., He, T. C., & Ren, G. (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes & diseases*, *5*(2), 77–106. https://doi.org/10.1016/j.gendis.2018.05.001
5. Fu, X., Tan, W., Song, Q., Pei, H., & Li, J. (2022). BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies. *Frontiers in cell and developmental biology*, *10*, 813457. https://doi.org/10.3389/fcell.2022.813457
6. Lee, A., Moon, B. I., & Kim, T. H. (2020). *BRCA1*/*BRCA2* Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies. *Annals of laboratory medicine*, *40*(2), 114–121. https://doi.org/10.3343/alm.2020.40.2.114
7. Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. *Cancers*, *13*(17), 4287. https://doi.org/10.3390/cancers13174287
8. Moo, T. A., Sanford, R., Dang, C., & Morrow, M. (2018). Overview of Breast Cancer Therapy. *PET clinics*, *13*(3), 339–354. https://doi.org/10.1016/j.cpet.2018.02.006
9. Nounou, M. I., ElAmrawy, F., Ahmed, N., Abdelraouf, K., Goda, S., & Syed-Sha-Qhattal, H. (2015). Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. *Breast cancer : basic and clinical research*, *9*(Suppl 2), 17–34. https://doi.org/10.4137/BCBCR.S29420
10. Ortega, M. A., Fraile-Martínez, O., Asúnsolo, Á., Buján, J., García-Honduvilla, N., & Coca, S. (2020). Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. *Journal of oncology*, *2020*, 9258396. https://doi.org/10.1155/2020/9258396
11. Paul, A., & Paul, S. (2014). The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. *Frontiers in bioscience (Landmark edition)*, *19*(4), 605–618. https://doi.org/10.2741/4230

12. Shahbandi, A., Nguyen, H. D., & Jackson, J. G. (2020). TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines. *Trends in cancer*, *6*(2), 98–110. https://doi.org/10.1016/j.trecan.2020.01.007
13. Shiovitz, S., & Korde, L. A. (2015). Genetics of breast cancer: a topic in evolution. *Annals of oncology : official journal of the European Society for Medical Oncology*, *26*(7), 1291–1299. https://doi.org/10.1093/annonc/mdv022
14. Smolarz, B., Nowak, A. Z., & Romanowicz, H. (2022). Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). *Cancers*, *14*(10), 2569. https://doi.org/10.3390/cancers14102569